ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Medical diagnostics company Biomoda, Inc. (OTCBB: BMOD) is taking preliminary steps to launch multisite Phase III clinical trials of its in-vitro diagnostic for early-stage lung cancer, trademarked under the name CyPath®.
